# Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists
#### (2022) - Food and Drug Administration
**Link**:: https://www.fda.gov/media/159663/download
**DOI**::
**Links**::
**Tags**:: #paper
**Cite Key**:: [@Food_and_Drug_Administration2022-be]
### Abstract
```
```
### Notes